Hypophosphatasia Treatment Market - 2024-2031

Report Overview

Global Hypophosphatasia Treatment Market reached US$ 841.9 million in 2023 and is expected to reach US$ 2785.10 million by 2031, growing at a CAGR of 16.1% during the forecast period 2024-2031

Hypophosphatasia is a rare inherited disorder causing defective bone and teeth mineralization and deficiency of serum and bone alkaline phosphatase activity. Six clinical forms are recognized: perinatal (lethal), benign, infantile, childhood, adult, and odontohypophosphatasia. In the lethal form, patients show impaired mineralization in utero, while in the benign form, symptoms improve spontaneously. Infantile symptoms include respiratory complications, premature craniosynostosis, demineralization, and metaphysis changes. Childhood symptoms include skeletal deformities, short stature, and waddling gait. Adult symptoms include stress fractures, thigh pain, chondrocalcinosis, and osteoarthropathy.

Market Dynamics: Drivers & Restraints

Rise in the prevalence of hypophosphatasia

The global hypophosphatasia treatment market is growing due to the increasing prevalence of the hypophosphatasia. As awareness and diagnostic capabilities improve, more cases are identified, leading to increased demand for treatment options. Enzyme replacement therapy, particularly Asfotase Alfa (Strensiq), has revolutionized management. Advancements in genetic testing and early diagnosis have increased the need for specialized therapies, fostering market expansion as pharmaceutical companies focus on innovative treatments for this rare condition.

For instance, in the United States, it affects approximately 500-600 individuals annually. In some inbred populations, such as Canadian Mennonites, the frequency is as high as 1 case per 2500 newborns. More than 250 distinct mutations have been described for the gene responsible for HPP, the vast majority (79%) of which are missense mutations.

Stringent regulatory requirements

The expansion of the hypophosphatasia market is also affected by the imposition of strict regulatory requirements and the limited availability of cures. This includes the necessity for extensive clinical studies on safety and efficacy of all new treatments before being licensed. At present, treatment is only partially effective, and there are no appropriate specific diagnostics for the disease. On top of that, there is very little knowledge about the pathology of hypophosphatasia which is a hindrance in treatment development. All these add to the difficulties in treatment progression of hypophosphatasia.

Market Segment Analysis

The global hypophosphatasia treatment market is segmented based on type, therapy type, end user and region.

The enzyme replacement therapy (ERT) from the therapy type segment accounted for approximately 45.3% of the hypophosphatasia treatment market share

The enzyme replacement therapy (ERT) from the therapy type segment accounted for approximately 45.3%. Asfotase alpha, which is an enzyme replacement therapy, has been approved for use and therefore it is the first drug of its kind to be given for treatment in the most severe pediatric cases of Hypophosphatasia (HPP) where treatment is needed. Asfotase alpha as recombinant human tissue non-specific alkaline phosphatase has to be administered subcutaneously.

The recommended dosage is 6 mg/kg body weight per week which can be divided into three or six weekly dosages of the drug. The drug has demonstrated favourable radiological and functional outcomes, improvements in respiratory functions as well as increases in overall survival rates in very ill children relative to a historical control group. Clinical evidence from each singular, severely affected patient adds to the evidence that the therapy is likely to provide highly beneficial impacts that are substantial.

For instance, in May 2024, Be Biopharma, a company that develops Engineered B Cell Medicines (BCMs), has presented preclinical research showing the production of active ALP by a BCM. This research, using CRISPR/Cas9 precision gene engineering and artificial intelligence-guided protein design, suggests BCMs as a potential treatment for Hypophosphatasia (HPP), an enzyme deficiency in people living with HPP. The findings were presented at the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting.

Moreover, on 28 June 2022, Sanofi, which is a France-based leading provider of treatments and vaccines revealed two approvals from the European Commission both for ERT treatments for rare diseases. This enables increasing awareness and accessibility for the global population.

Market Geographical Analysis

North America is estimated to hold about 38.4% of the total market share throughout the forecast period

North America is estimated to hold about 38.4% of the total market share throughout the forecast period due to significant investments in biomedical research and the rapid adoption of digital tools in diagnostic centers, particularly in the treatment of hypophosphatasia, a rare genetic disorder affecting bone development and mineral metabolism.

For instance, in January 2023, Rallybio Corporation, a clinical-stage biotechnology company, announced recent achievements and clinical milestones for 2023, contributing to market revenue growth in various countries. The company aims to identify and accelerate the development of life-changing therapies for patients with severe and rare diseases, while also expanding its earlier-stage pipeline through strategic business development efforts.

Market Segmentation

By Type

Odontohypophosphatasia

Pseudohypophosphatasia

Others

By Therapy Type

Enzyme Replacement Therapy (ERT)

Supportive Therapies

Analgesic-antiphlogistic therapy

Bone-targeted treatment

Others

By End User

Hospitals

Specialty Clinics

Homecare Settings

Research Institutes

By Region

North America

U.S.

Canada

Mexico

Europe

Germany

UK

France

Italy

Spain

Rest of Europe

South America

Brazil

Argentina

Rest of South America

Asia-Pacific

China

India

Japan

South Korea

Rest of Asia-Pacific

Middle East and Africa

Market Competitive Landscape

The major global players in the market include Purec Global, Alexion Pharmaceuticals, Inc, AM-Pharma B.V., Aastrom Biosciences, Inc, Rallybio, Biomarin, Pfizer Inc, Protalix Biotherapeutics, Sanofi among others.

Key Developments

In October 2023, AM-Pharma B.V. reported positive clinical data from a Phase 1b study of its patented recombinant alkaline phosphatase, ilofotase alfa, as a potential enzyme replacement therapy for adult hypophosphatasia patients.

Why Purchase the Report?

To visualize the global hypophosphatasia treatment market segmentation based on type, therapy type, end user and region as well as understand key commercial assets and players.

Identify commercial opportunities by analyzing trends and co-development.

Excel data sheet with numerous data points of the hypophosphatasia treatment market level with all segments.

PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.

Product mapping available as excel consisting of key products of all the major players.

The global hypophosphatasia treatment market report would provide approximately 64 tables, 61 figures, and 186 pages.

Target Audience 2024

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies